Samsung Biologics has reportedly got another patent lawsuit. Back in January, US pharmaceutical company Regeneron filed a patent infringement and prevention claim against Samsung Biologics and its subsidiary Samsung Bioepis in Seoul Central District Court in Korea.
The matter is related to the copycat drug being developed by Samsung Bioepis infringing on some patents on its eye disease treatment (Eylea), which it registered with the Korean Intellectual Property Office.
The total sales of Eylea hit US$7.7 billion (10.2641 trillion won) in 2022. But Eylea’s patent expires in June of this year in the United States and May 2024 in Europe.
Other reports also claimed that regeneron has been engaged in a patent dispute with Samsung Bioepis at Korea’s Intellectual Property Trial and Appeal Board since October 2022.
In Q1 2023 Samsung Biologics recorded a revenue of KRW 720.9 billion and an operating profit of KRW 191.7 billion. The performance in the first quarter of this year was driven by the stable growth of the contract manufacturing and development (CDMO) business and the connection to Samsung Bioepis’ performance. Both the combined sales of the two companies and the separate sales of Samsung Biologics are the largest ever.
